Table 1 Baseline study characteristics (n = 26)
Study characteristics | No. of trials (%) |
|---|---|
Cancer type | |
Mixed | 7 (27) |
Head and neck cancer | 5 (19) |
Prostate cancer | 3 (12) |
Lung cancer | 3 (12) |
Breast cancer | 3 (12) |
Rectal cancer | 2 (8) |
Oesopho-gastric cancer | 1 (4) |
Pancreatic cancer | 1 (4) |
Pelvic cancer | 1 (4) |
Primary outcome | |
Clinical endpoint | 16 (62) |
Patient-reported endpoint | 10 (39) |
Intervention | |
Systemic therapy | 4 (15) |
Symptom control | 4 (15) |
Radiotherapy | 3 (12) |
Medical device | 3 (12) |
Complementary therapy | 3 (12) |
Patient-directed therapy | 3 (12) |
Dietary | 2 (8) |
Analgesic | 1 (4) |
Diagnostic | 1 (4) |
Supportive care | 1 (4) |
Bariatric therapy | 1 (4) |
Trial design | |
RCT | 19 (73) |
Single-arm trial | 5 (19) |
Randomised cross-over trial | 2 (8) |
Number of centres | |
Singe-centre | 17 (65) |
Multi-centre | 9 (35) |
Funding | |
Academic | 19 (73) |
Industry | 3 (12) |
Hybrid | 2 (8) |
Unknown | 2 (8) |
Planned sample size | |
< 100 | 15 (58) |
100–199 | 8 (31) |
> 200 | 3 (12) |
Sample size reached (N = 22)* | |
Yes | 13 (59) |
No | 9 (41) |